GREENWOOD VILLAGE, Colo., July 18, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ & Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced the closing of a $17,839,120 underwritten public offering of 5,488,960 shares of common stock, including 692,310 shares of common stock which were sold by Ampio and certain of its stockholders pursuant to the exercise of the underwriters' over-allotment option, at a price of $3.25 per share. Ampio received gross proceeds of $16,912,545 from the offering and the selling stockholders received gross proceeds of $926,575 from the offering. Ampio will not receive any of the proceeds from the sale of shares by the selling stockholders.
Aegis Capital Corp. and Fordham Financial Management, Inc. acted as joint book-running managers for the offering.
The offering was made pursuant to a shelf registration statement that Ampio filed with the Securities and Exchange Commission ("SEC") and is effective. The prospectus supplements relating to the offering were filed with the SEC and are available on the website of the SEC at http://www.sec.gov. Copies of the prospectus supplements relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643, New York, New York 10004.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.
This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contact: Rick Giles, Investor Relations, Ampio Pharmaceuticals, Inc. 720-437-6500
|SOURCE Ampio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved